生物技术领域的合作研究协议（2020-2026）

本报告调查并分析了全球生物技术领域的合作研究伙伴关係，详细阐述了生物技术公司如何建立合作关係、协商财务条款以及分担研发和商业化责任。

目录

摘要整理

第一章：引言

第二章：合作研究协议的趋势

• 引言
• 合作研究协议的定义
• 合作研究协议的趋势（2020年至今）
  • 合作研究协议：依年份
  • 合作研究协议：依研发阶段
  • 合作研究协议：依行业
  • 合作研究协议：依治疗领域
  • 合作研究协议：依技术类型
  • 最活跃公司的合作研究协议
• 进行合作研究的原因协议
• 合作研究协议的未来

第三章 合作研究协议架构概述

• 引言
• 合作研究协议结构

第四章：主要合作研究协议

• 引言
• 依价值排名的顶级合作研究协议

第五章：最活跃的25家合作研究公司

• 引言
• 最活跃的25家合作研究公司

第六章：合作研究协议（含合约目录）

• 引言
• 包含合约文件的合作研究协议
• 合约目录
• 合约目录 - 合作研究协议：依公司（A-Z）
• 合约目录 - 合作研究协议：依治疗领域
• 合约目录 - 合作研究协议：依技术类型
• 生物製药研究股份有限公司简介
• 当前合作项目
• 当前协议
• 目前合作项目近期报告标题

Benchmark Collaboration Partnerships Across the Global Biotechnology Industry

Free report sample

The Collaboration Deals in Biotechnology report provides a comprehensive analysis of collaboration partnerships across the biotechnology sector. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how biotech companies structure collaborative alliances, negotiate financial terms, and share development and commercialization responsibilities.

Fully revised and updated, the report includes 2,096 collaboration deals announced between 2020 and 2026, offering an extensive view of partnering activity across the biotechnology landscape. Each deal record includes financial information where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

Whether you are benchmarking deal structures, identifying potential partners, or conducting due diligence on collaboration strategies, this report provides the data-driven insights and contract-level visibility needed to support better partnership decisions.

Key Benefits

• Save Significant Research Time

Access over 2,000 collaboration deals in a single resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Collaboration Deal Structures

Understand how biotechnology companies structure collaboration partnerships, including development roles, rights allocation, and commercialization responsibilities.

• Analyze Financial Terms with Confidence

Review disclosed payment structures such as upfront payments, milestone payments, and other financial terms to benchmark industry deal values.

• Access Real Contract Documents

Where available, explore actual collaboration agreements filed with the SEC, providing detailed insight into deal provisions beyond press release disclosures.

• Identify the Most Active Collaboration Dealmakers

Discover which biotechnology companies are most active in collaboration partnerships and analyze their partnering strategies.

• Track Industry Trends

Analyze collaboration dealmaking activity across companies, therapeutic areas, and technology types to understand how partnership strategies are evolving.

What's Included in the Report

Analysis of collaboration dealmaking trends since 2020

Overview of collaboration partnership structures and financial models

Review of leading collaboration deals by disclosed value

Profiles of the most active collaboration dealmakers

Detailed analysis of deals by company, therapeutic area, and technology type

A comprehensive deal directory covering all collaboration agreements announced since 2020

Links to online deal records, including contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual collaboration contracts, the report enables users to evaluate key partnership provisions such as:

• Rights granted or optioned
• Financial payment structures and milestone triggers
• Intellectual property ownership and licensing rights
• Development and commercialization responsibilities
• Exclusivity provisions and partnership governance
• Deal duration and termination clauses
• Why This Report Matters
• Collaboration partnerships are a cornerstone of innovation in biotechnology, enabling companies to combine technologies, share development risk, and accelerate the advancement of new therapies.
• This report provides the real-world deal data, financial benchmarking, and contract insight needed to structure stronger collaborations, negotiate better terms, and identify the right partners.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaboration dealmaking

• 2.1. Introduction
• 2.2. Definition of collaboration deal
• 2.3. Trends in collaboration deals since 2020
  • 2.3.1. Collaboration dealmaking by year
  • 2.3.2. Collaboration dealmaking by phase of development
  • 2.3.3. Collaboration dealmaking by industry sector
  • 2.3.4. Collaboration dealmaking by therapy area
  • 2.3.5. Collaboration dealmaking by technology type
  • 2.3.6. Collaboration dealmaking by most active company
• 2.4. Reasons for entering into collaboration partnering deals
• 2.5. The future of collaboration deals

Chapter 3 - Overview of collaboration deal structure

• 3.1. Introduction
• 3.2. Collaboration agreement structure

Chapter 4 - Leading collaboration deals

• 4.1. Introduction
• 4.2. Top collaboration deals by value

Chapter 5 - Top 25 most active collaboration dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active collaboration dealmakers

Chapter 6 - Collaboration deals including contracts directory

• 6.1. Introduction
• 6.2. Collaboration deals with contracts
• Deal directory
• Deal directory - collaboration dealmaking by companies A-Z
• Deal directory - collaboration dealmaking by therapy area
• Deal directory - collaboration dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of collaboration deal
• Figure 2: Trends in collaboration deal announcements
• Figure 3: Collaboration deals signed at each phase of development
• Figure 4: Collaboration deals by industry sector
• Figure 5: Collaboration deals by therapy area
• Figure 6: Collaboration deals by technology type
• Figure 7: Top 25 most active collaboration dealmakers
• Figure 8: Top collaboration deals by value
• Figure 9: Most active collaboration dealmakers